Markus Grabbert

Join us for the Radiation Therapy in Prostate Cancer Symposium in Freiburg on the 19th-20th of July 2024, meet international experts in uro-oncology and present your own research in the poster session. Programm and registration via uniklinik-freiburg.de/prostate-cance… Accredited by @degro_ev

The fantastic @Uroweb @AmerUrological exchange continues in #Freiburg with the great @cgratzke ! So many wonderful experiences that I will cherish forever. Grateful for new friends and collaborators! @MalteRieken @MarkusGrabbert @GBonkat @boyd_viersMD @august_sigle

#EAU #AUA exchange program with wonderful @Scarps_kristen @boyd_viersMD at @Uniklinik_Fr, having dinner with our friends from @Uroweb guidelines member @GBonkat and @EurUrolFocus ass. editor @MalteRieken in #Basel - what an experience! @AmerUrological @Uroweb @MarkusGrabbert

💫🌟Disappointing update from #ESMO23: Dr. Christina Gratzke reveals KEYNOTE-991 study results, emphasizing the complexities of treating metastatic hormone-sensitive prostate cancer (mHSPC). Here's what we've learned: 🔵 KEYNOTE-991 Study Insights: - Study halted: Pembro + Enza + ADT didn't improve outcomes in mHSPC patients, escalating risks instead 🛑 - rPFS, OS, and TT SSE outcomes were comparable between Pembro + Enza vs PBO + Enza groups 📉 - Significant increase in Grade ≥3 Treatment-Related Adverse Events (TRAEs) observed with the combination therapy 💊 🌟This setback highlights the challenges in prostate cancer research and underscores the importance of rigorous evaluation in clinical trials. 💪 Research continues for better solutions in the fight against mHSPC. @OncoAlert  @cgratzke @urologysummit @OncBrothers @neerajaiims @amerseburger @mishabeltran #CancerResearch #ClinicalTrials #MedicalScience

Neoadjuvant atezo in non-urothelial cancer subtypes led by @b_szabados @BartsECMC #ESMO23 . Firstly, the inconsistency in pathology review is problematic. Secondly, the responders in the sarcomatoid group was very high - as in renal cancer. These patients need IO at some point.

A monumental moment for bladder cancer today. A privilege to have worked on this trial which will change the landscape of bladder cancer. 👏🏻

#ASCO23 @ASCO @DrChoueiri present the data on Contact-3 trial which addresses a major question in the #mRCC #kidneycancer field 👉Is there a role of ICI Re-challenge? Answer is “NO”. This study does change my practice in many patients. Congrats for the simultaneous @theLancet publication led by @montypal 👇 @OncoAlert @kidneycan @urotoday

#ASCO23 @SWOG S1011: With radical cystectomy for muscle invasive #bladdercancer, extended lymphadenectomy is not assoc w improved DFS or OS compared to standard node dissection @slernerbcmedu1 oral pres Mon, June 5, 1:54 pm, Hall D1 @bladdercancerus #blcsm swog.org/news-events/ne…

@urotoday @Uniklinik_Fr @ASCO @WallisCJD @UofT Great team effort showing the strength of interdisciplinary research! PSMA-PET is entering nomograms for salvage RT. @nina_hegemann @Simon_Spohn @drlouiseemmett @andrea_farolfi @stefanofanti4 @LMU_RadOnc @Mat_Guc @AncaGrosu1 @Josephgunner @goc_cy #GU23

Die Urologische Klinik des Universitätsklinikum Freiburg bedankt sich bei allen Mitarbeiter:innen und Kooperationspartner:innen für die gute Zusammenarbeit im vergangenen Jahr. Frohe Weihnachten! lnkd.in/e9HJn69S

#ASTRO2022 has been packed with loads of great contributions. Here are some of the highlights: ➡️ 7 years outcomes of the phase 3 PCS5 trial: MHRT of 68 Gy in 25 fx is non-inferior to 76 Gy in 38 fx in high risk PCa patients. 7 year BCR 87% (MHRT) vs 85% (NFRT). @niazi_Dr7

Check out our paper by Simon Kirste, @RuehleAlex, @AncaGrosu1, @SimonLo21054188 and others from @Uniklinik_Fr ▶️1st prospective study about #SBRT for RCC in VHL pts ▶️Median f/u 43 mo ▶️2-year LC 100% ▶️2-year OS 85.7% ▶️No grade ≥2 tox mdpi.com/1888422 #radonc

Today we treated our first patient within the #HypoFocal-SBRT trial @RadOnc_UKF. Great collective efforts by the whole team @Uniklinik_Fr @AncaGrosu1 @CZamboglou @Simon_Spohn . We can’t wait for the other Centers to join in!!!🙌🙌 @degro_ev #radonc

To all young urologists out there - the answer to the question "who do you want to be like when your grow up" should be @cgratzke! Too many good things to say in 280 characters about what Christian is doing in the Urologische Klinik @Uniklinik_Fr. Thanks for memorable visit!

New Platinum Priority Editorial from @TDorffOnc @CaPsurvivorship A Path to Precision Medicine in Prostate Cancer: Learning from “Negative” Trials of Targeted Therapies buff.ly/3Q6FsDV

Novel bladder immune performance index (BIPI) developed by using a combined real world clinico-genomic database. RWD can support future clinical trial designs and may lead to innovative new treatment approaches. #imFLAME #imCORE

Current Issue: Long-term Clinical Outcomes of Repeat Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: A Case Series buff.ly/3OjN5px @MarkusGrabbert @august_sigle @CZamboglou @cgratzke #clinicaloutcomes #urology

Seminar des Arbeitskreises Urologische Funktionsdiagnostik und Urologie der Frau mit spannenden Themen zur funktionellen Urologie in der kommenden Woche in Berlin. Anmeldung unter: solution-akademie-veranstaltungen.de/uroaktuell

✔️#UroAktuell: Sind Sie schon angemeldet? Noch bis 15. April 2022 kann der Frühbucherrabatt genutzt werden ‼️ #dgu22 solution-akademie-veranstaltungen.de/uroaktuell @BDUrologie @GesruAcademics @GeSRU_de @EvidenceUro @AFUrologie @amerseburger @wulfingc @docmeetings @uronauten @aegnord

We’re happy to announce that the PIONEER #BigData platform is growing: A new data sharing agreement has been signed with @Prof. Gratzke from @UniFreiburg. More info will follow soon. @BD4BO @IMI_JU